WisdomTree BioRevolution FundWDNA
WDNA
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.72% more ownership
Funds ownership: 9.97% [Q3] → 10.69% (+0.72%) [Q4]
0% more funds holding
Funds holding: 3 [Q3] → 3 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
7% less capital invested
Capital invested by funds: $247K [Q3] → $230K (-$17K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for WDNA.
Financial journalist opinion
Neutral
Seeking Alpha
2 weeks ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Positive
ETF Trends
3 months ago
Opportunities in Biotechnology Will Follow Advancements in the Science
By Christopher Gannatti, CFA Key Takeaways Recent advancements in GLP-1 drugs, such as Ozempic and Wegovy, underscore their potential to transform health care by addressing obesity, cardiovascular diseases and even neurodegenerative conditions.
Neutral
ETF Trends
1 year ago
Why We Loved Bill Gates's Annual Letter
By Christopher Gannatti, CFA, Global Head of Research We have been writing a lot about artificial intelligence (AI) and the ways in which we believe that topic will continue to evolve as the calendar changes from 2023 to 2024.
Positive
ETF Trends
1 year ago
Wager on WDNA for Biotech Rebound
It's been a lengthy of stretch of subpar performance by biotech stocks and related exchange traded funds. That's a scenario that will repeat this year.
Charts implemented using Lightweight Charts™